While Big Pharma chases systemic drugs with heavy side effects, Azitra is rewriting the rules of dermatology from the skin's surface up. They aren't just treating symptoms; they're engineering the skin microbiome to correct the genetic errors driving autoimmune conditions like psoriasis.

"Azitra is moving beyond topical steroids—engineering skin bacteria to deliver biologics directly where the disease lives."

The company's leadership, including VP of Chemistry Roger Leger and COO Travis Whitfill, brings a formulation-heavy background. This suggests a focus on delivery mechanisms—a critical bottleneck in dermatological biologics. Their tech stack (Tailwind, Bootstrap, Cloudflare) is standard, but the 'undefined' traffic regions (74% and 25% of traffic) hint at a stealth mode or early-stage regional testing grounds rather than a polished global marketing machine.

• Microbial Engineering: Using bacteria as 'factories' for therapeutic proteins.
• Localized Delivery: Aiming to reduce systemic side effects common in biologics.
• Niche Focus: Targeting specific genetic markers in skin disorders rather than general inflammation.